• BridgeBio Pharma has announced that long-term efficacy and safety results from the open-label extension of its Phase 3 ATTRibute-CM trial of acoramidis in ATTR-CM, including multiple analyses on survival, disease stabilization, and patient-reported outcomes, were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans on March 28–30, 2026.
• The new data, alongside real-world survey findings on treatment patterns and preferences in ATTR-CM, offer a deeper view of how Attruby’s transthyretin-stabilizing profile and tolerability may influence clinical use in everyday cardiology practice.
• With long-term ATTRibute-CM extension data highlighting survival and disease stabilization themes, we’ll examine how this fresh evidence feeds into BridgeBio’s investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 26 companies in the world exploring or producing it. Find the list for free.

BridgeBio Pharma Investment Narrative Recap

To own BridgeBio, you need to believe Attruby can anchor a durable ATTR-CM franchise while the broader rare disease pipeline matures into multiple commercial products. The new long term ATTRibute-CM data, focused on survival, disease stabilization, and patient reported outcomes, ties directly into Attruby’s near term commercial ramp, but does not remove the key risk that BridgeBio still runs high losses and depends heavily on a single cardiovascular asset today.

The most relevant recent announcement is BridgeBio’s March 23 update that long term ATTRibute-CM open label extension data and real world ATTR-CM treatment survey results will be featured in a late breaking oral session and three posters at ACC 2026. These readouts sit right beside upcoming regulatory and launch milestones for BBP 418 and infigratinib, and could shape how payers, cardiologists, and competitors frame Attruby’s place in the ATTR-CM treatment mix.

Yet while Attruby’s profile is improving, you still need to weigh the risk that high operating costs and heavy ATTR-CM reliance could pressure future shareholder returns if...

BridgeBio Pharma's narrative projects $1.7 billion revenue and $297.7 million earnings by 2028. This requires 92.3% yearly revenue growth and about a $1.07 billion earnings increase from $-776.4 million.

Uncover how BridgeBio Pharma's forecasts yield a $100.05 fair value, a 44% upside to its current price.

Exploring Other Perspectives

Before this ACC data, the most pessimistic analysts were assuming BridgeBio might reach about US$1.1 billion in revenue and US$176.4 million in earnings by 2028, which is far more cautious than narratives that lean on Attruby’s success and the broader pipeline to drive faster improvement, so it is worth asking how this new ATTR-CM evidence might shift those expectations and what that could mean for your own view of the stock.

Explore 9 other fair value estimates on BridgeBio Pharma - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BridgeBio Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BridgeBio Pharma's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 61 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.